Funding extension brings in $8M for antibody drug developer

04/1/2013 | MedCityNews.com

Theraclone Sciences secured an additional $8 million, bringing the total raised in its Series B funding round to $50 million. The Seattle biotech company is developing two antibodies for severe flu and cytomegalovirus infection.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY